H
Henry R. Black
Researcher at Rush University Medical Center
Publications - 207
Citations - 92296
Henry R. Black is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Blood pressure & Prehypertension. The author has an hindex of 74, co-authored 206 publications receiving 88350 citations. Previous affiliations of Henry R. Black include University of Erlangen-Nuremberg.
Papers
More filters
Journal ArticleDOI
Graded Blood Pressure Reduction in Hypertensive Outpatients Associated With Use of a Device to Assist With Slow Breathing
William J. Elliot,Joseph L. Izzo,William B. White,Douglas R. Rosing,Christopher S. Snyder,Ariela Alter,Benjamin Gavish,Henry R. Black +7 more
TL;DR: Even without training, hypertensive patients who receive a device to guide slow breathing significantly lowered their office SBP if the total time spent in slow breathing over 8 weeks exceeded a "threshold" value of 180 minutes.
Journal ArticleDOI
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Richard H. Grimm,Karen L. Margolis,Vasilios Papademetriou,William C. Cushman,Charles E. Ford,Judy Bettencourt,Michael H. Alderman,Jan Basile,Henry R. Black,Vincent DeQuattro,John H. Eckfeldt,C. Morton Hawkins,H. Mitchell Perry,Michael A. Proschan +13 more
TL;DR: The ALLHAT study is a randomized, double-blind, active-controlled clinical trial designed to determine whether the incidence of the primary outcome, fatal coronary heart disease or nonfatal myocardial infarction, differs between treatment initiation with a diuretic versus each of 3 other antihypertensive drugs.
Journal ArticleDOI
Goal-Oriented Hypertension Management: Translating Clinical Trials to Practice
TL;DR: Although DBP control was easy to achieve, achieving SBP goal still remained difficult, Employing goal-oriented management can translate BP control results achieved in clinical trials into outpatient practice.
Journal ArticleDOI
Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial
Henry R. Black,William J. Elliott,James D. Neaton,Gregory A Grandits,Patricia Grambsch,Richard H. Grimm,Lennart Hansson,Yves Lacoucière,James E. Muller,Peter Sleight,Michael A. Weber,William B. White,Gordon H. Williams,Janet Wittes,Alberto Zanchetti,T. Daniel Fakouhi +15 more
TL;DR: The Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial is a randomized, prospective, double-blind, parallel-group, two-arm, actively controlled, multicenter, international 5-year clinical trial involving 15,000 patients.
Journal ArticleDOI
Comparison of Effects of Controlled Onset Extended Release Verapamil at Bedtime and Nifedipine Gastrointestinal Therapeutic System on Arising on Early Morning Blood Pressure, Heart Rate, and the Heart Rate–Blood Pressure Product
William B. White,Henry R. Black,Michael A. Weber,William J. Elliott,Brian Bryzinski,T. Daniel Fakouhi +5 more
TL;DR: In this article, the effects of a chronotherapeutic agent (controlled-onset extended release [COER] verapamil), administered at bedtime versus a conventional, homeostatic therapy (nifedipine gastrointestinal therapeutic system [GITS]) taken in the morning, on early morning and 24-hour blood pressure (BP), heart rate (HR), and the HR x systolic BP product during the 4 hours from 1 hour before to 3 hours after awakening were evaluated.